Streetwise Reports' Article Archives — July 2015 back to current month (5)
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. In this interview with The Life Sciences Report, Corner brings important names to investors' attention.
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement. In this interview, Brian Marckx, senior medical device/diagnostics analyst with Zacks Investment Research, tells The Life Sciences Report how that situation is changing and identifies some innovative companies poised to make the most of the situation.
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies. In this interview with The Life Sciences Report, Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.
The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront.
|"DRRX's capital raise takes care of financing overhang on the stock."|